Sodium-glucose cotransporter 2 inhibitors influence skeletal muscle pathology in patients with heart failure and reduced ejection fraction.
Atrophy
HFrEF
Metabolism
Muscle
SGLT2 inhibitors
Journal
European journal of heart failure
ISSN: 1879-0844
Titre abrégé: Eur J Heart Fail
Pays: England
ID NLM: 100887595
Informations de publication
Date de publication:
11 Mar 2024
11 Mar 2024
Historique:
revised:
12
01
2024
received:
30
11
2023
accepted:
23
02
2024
medline:
12
3
2024
pubmed:
12
3
2024
entrez:
12
3
2024
Statut:
aheadofprint
Résumé
Patients with heart failure and reduced ejection fraction (HFrEF) exhibit skeletal muscle pathology, which contributes to symptoms and decreased quality of life. Sodium-glucose cotransporter 2 inhibitors (SGLT2i) improve clinical outcomes in HFrEF but their mechanism of action remains poorly understood. We aimed, therefore, to determine whether SGLT2i influence skeletal muscle pathology in patients with HFrEF. Muscle biopsies from 28 male patients with HFrEF (New York Heart association class I-III) treated with SGLT2i (>12 months) or without SGLT2i were compared. Comprehensive analyses of muscle structure (immunohistochemistry), transcriptome (RNA sequencing), and metabolome (liquid chromatography-mass spectrometry) were performed, and serum inflammatory profiling (ELISA). Experiments in mice (n = 16) treated with SGLT2i were also performed. Myofiber atrophy was ~20% less in patients taking SGLT2i (p = 0.07). Transcriptomics and follow-up measures identified a unique signature in patients taking SGLT2i related to beneficial effects on atrophy, metabolism, and inflammation. Metabolomics identified influenced tryptophan metabolism in patients taking SGLT2i: kynurenic acid was 24% higher and kynurenine was 32% lower (p < 0.001). Serum profiling identified that SGLT2i treatment was associated with lower (p < 0.05) pro-inflammatory cytokines by 26-64% alongside downstream muscle interleukin (IL)-6-JAK/STAT3 signalling (p = 008 and 0.09). Serum IL-6 and muscle kynurenine were correlated (R = 0.65; p < 0.05). Muscle pathology was lower in mice treated with SGLT2i indicative of a conserved mammalian response to treatment. Treatment with SGLT2i influenced skeletal muscle pathology in patients with HFrEF and was associated with anti-atrophic, anti-inflammatory, and pro-metabolic effects. These changes may be regulated via IL-6-kynurenine signalling. Together, clinical improvements following SGLT2i treatment in patients with HFrEF may be partly explained by their positive effects on skeletal muscle pathology.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
Références
Hobbs FD, Kenkre JE, Roalfe AK, Davis RC, Hare R, Davies MK. Impact of heart failure and left ventricular systolic dysfunction on quality of life: A cross-sectional study comparing common chronic cardiac and medical disorders and a representative adult population. Eur Heart J 2002;23:1867-1876. https://doi.org/10.1053/euhj.2002.3255
Wood N, Straw S, Scalabrin M, Roberts LD, Witte KK, Bowen TS. Skeletal muscle atrophy in heart failure with diabetes: From molecular mechanisms to clinical evidence. ESC Heart Fail 2021;8:3-15. https://doi.org/10.1002/ehf2.13121
Anker SD, Ponikowski P, Varney S, Chua TP, Clark AL, Webb-Peploe KM, et al. Wasting as independent risk factor for mortality in chronic heart failure. Lancet 1997;349:1050-1053. https://doi.org/10.1016/S0140-6736(96)07015-8
Anker SD, Butler J, Filippatos G, Khan MS, Marx N, Lam CSP, et al. Effect of empagliflozin on cardiovascular and renal outcomes in patients with heart failure by baseline diabetes status: Results from the EMPEROR-Reduced trial. Circulation 2021;143:337-349. https://doi.org/10.1161/CIRCULATIONAHA.120.051824
McMurray JJV, Solomon SD, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, et al.; DAPA-HF Trial Committees and Investigators. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med 2019;381:1995-2008. https://doi.org/10.1056/NEJMoa1911303
Butt JH, Docherty KF, Kosiborod MN, Inzucchi SE, Køber L, Langkilde AM, et al. Dapagliflozin and physical and social activity limitations in heart failure with reduced ejection fraction. JACC Heart Fail 2023;11:1411-1423. https://doi.org/10.1016/j.jchf.2023.04.016
Palau P, Amiguet M, Domínguez E, Sastre C, Mollar A, Seller J, et al.; DAPA-VO2 Investigators. Short-term effects of dapagliflozin on maximal functional capacity in heart failure with reduced ejection fraction (DAPA-VO2): A randomized clinical trial. Eur J Heart Fail 2022;24:1816-1826. https://doi.org/10.1002/ejhf.2560
Packer M. Six lessons learned from the use of SGLT2 inhibitors in patients with heart failure. Nat Rev Cardiol 2022;19:499-500. https://doi.org/10.1038/s41569-022-00736-3
Mulder S, Hammarstedt A, Nagaraj SB, Nair V, Ju W, Hedberg J, et al. A metabolomics-based molecular pathway analysis of how the sodium-glucose co-transporter-2 inhibitor dapagliflozin may slow kidney function decline in patients with diabetes. Diabetes Obes Metab 2020;22:1157-1166. https://doi.org/10.1111/dom.14018
Santos-Gallego CG, Mayr M, Badimon J. SGLT2 inhibitors in heart failure: Targeted metabolomics and energetic metabolism. Circulation 2022;146:819-821. https://doi.org/10.1161/CIRCULATIONAHA.122.060805
Winzer EB, Schauer A, Langner E, Augstein A, Goto K, Männel A, et al. Empagliflozin preserves skeletal muscle function in a HFpEF rat model. Int J Mol Sci 2022;23:10989. https://doi.org/10.3390/ijms231910989
Nambu H, Takada S, Fukushima A, Matsumoto J, Kakutani N, Maekawa S, et al. Empagliflozin restores lowered exercise endurance capacity via the activation of skeletal muscle fatty acid oxidation in a murine model of heart failure. Eur J Pharmacol 2020;866:172810. https://doi.org/10.1016/j.ejphar.2019.172810
Hirata Y, Nomura K, Senga Y, Okada Y, Kobayashi K, Okamoto S, et al. Hyperglycemia induces skeletal muscle atrophy via a WWP1/KLF15 axis. JCI insight 2019;4:e124952. https://doi.org/10.1172/jci.insight.124952
Wells DJ. What is the level of dystrophin expression required for effective therapy of duchenne muscular dystrophy? J Muscle Res Cell Motil 2019;40:141-150. https://doi.org/10.1007/s10974-019-09535-9
Selvaraj S, Fu Z, Jones P, Kwee LC, Windsor SL, Ilkayeva O, et al.; DEFINE-HF Investigators. Metabolomic profiling of the effects of dapagliflozin in heart failure with reduced ejection fraction: DEFINE-HF. Circulation 2022;146:808-818. https://doi.org/10.1161/CIRCULATIONAHA.122.060402
Weiss K, Schar M, Panjrath GS, Zhang Y, Sharma K, Bottomley PA, et al. Fatigability, exercise intolerance, and abnormal skeletal muscle energetics in heart failure. Circ Heart Fail 2017;10:e004129. https://doi.org/10.1161/CIRCHEARTFAILURE.117.004129
Ferrannini E, Baldi S, Frascerra S, Astiarraga B, Heise T, Bizzotto R, et al. Shift to fatty substrate utilization in response to sodium-glucose cotransporter 2 inhibition in subjects without diabetes and patients with type 2 diabetes. Diabetes 2016;65:1190-1195. https://doi.org/10.2337/db15-1356
Xue C, Li G, Zheng Q, Gu X, Shi Q, Su Y, et al. Tryptophan metabolism in health and disease. Cell Metab 2023;35:1304-1326. https://doi.org/10.1016/j.cmet.2023.06.004
Savitz J. The kynurenine pathway: A finger in every pie. Mol Psychiatry 2020;25:131-147. https://doi.org/10.1038/s41380-019-0414-4
Agudelo LZ, Ferreira DMS, Cervenka I, Bryzgalova G, Dadvar S, Jannig PR, et al. Kynurenic acid and Gpr35 regulate adipose tissue energy homeostasis and inflammation. Cell Metab 2018;27:378-392.e5. https://doi.org/10.1016/j.cmet.2018.01.004
Kim SR, Lee SG, Kim SH, Kim JH, Choi E, Cho W, et al. SGLT2 inhibition modulates NLRP3 inflammasome activity via ketones and insulin in diabetes with cardiovascular disease. Nat Commun 2020;11:2127. https://doi.org/10.1038/s41467-020-15983-6
Hirata Y, Nomura K, Kato D, Tachibana Y, Niikura T, Uchiyama K, et al. A Piezo1/KLF15/IL-6 axis mediates immobilization-induced muscle atrophy. J Clin Invest 2022;132:1-13. https://doi.org/10.1172/JCI154611
Gielen S, Sandri M, Kozarez I, Kratzsch J, Teupser D, Thiery J, et al. Exercise training attenuates MuRF-1 expression in the skeletal muscle of patients with chronic heart failure independent of age: The randomized Leipzig Exercise Intervention in Chronic Heart Failure and Aging catabolism study. Circulation 2012;125:2716-2727. https://doi.org/10.1161/CIRCULATIONAHA.111.047381
Mooney L, Jackson CE, Adamson C, McConnachie A, Welsh P, Myles RC, et al. Adverse outcomes associated with interleukin-6 in patients recently hospitalized for heart failure with preserved ejection fraction. Circ Heart Fail 2023;16:e010051. https://doi.org/10.1161/CIRCHEARTFAILURE.122.010051
Moresi V, Adamo S, Berghella L. The JAK/STAT pathway in skeletal muscle pathophysiology. Front Physiol 2019;10:500. https://doi.org/10.3389/fphys.2019.00500
Enko D, Zelzer S, Wenninger J, Holasek S, Schnedl WJ, Baranyi A, et al. Interleukin-6 is associated with tryptophan metabolism and signs of depression in individuals with carbohydrate malabsorption. EXCLI J 2020;19:1414-1422. https://doi.org/10.17179/excli2020-2940
Kaiser H, Yu K, Pandya C, Mendhe B, Isales CM, McGee-Lawrence ME, et al. Kynurenine, a tryptophan metabolite that increases with age, induces muscle atrophy and lipid peroxidation. Oxid Med Cell Longev 2019;2019:9894238. https://doi.org/10.1155/2019/9894238
Xie T, Lv T, Zhang T, Feng D, Zhu F, Xu Y, et al. Interleukin-6 promotes skeletal muscle catabolism by activating tryptophan-indoleamine 2,3-dioxygenase 1-kynurenine pathway during intra-abdominal sepsis. J Cachexia Sarcopenia Muscle 2023;14:1046-1059. https://doi.org/10.1002/jcsm.13193
Konishi M, Ebner N, Springer J, Schefold JC, Doehner W, Dschietzig TB, et al. Impact of plasma kynurenine level on functional capacity and outcome in heart failure - results from Studies Investigating Co-Morbidities Aggravating Heart Failure (SICA-HF). Circ J 2016;81:52-61. https://doi.org/10.1253/circj.CJ-16-0791
Hinkley JM, Yu GX, Standley RA, Distefano G, Tolstikov V, Narain NR, et al. Exercise and ageing impact the kynurenine/tryptophan pathway and acylcarnitine metabolite pools in skeletal muscle of older adults. J Physiol 2023;601:2165-2188. https://doi.org/10.1113/JP284142